University of Chicago Medicine Comprehensive Cancer Center researchers have found a new treatment for advanced prostate cancer. They achieved complete tumor control and extended survival in a mouse model of prostate cancer using a three-drug regimen that targets PI3K, MEK, and Wnt/β-catenin signaling pathways. The intermittent dosing doesn’t cause long-term side effects, and a success rate of 100% was observed in the model.
Third-Party Risk Management: Best Practices for Protecting Your Business
Third-party risk management is crucial for businesses as they increasingly rely on outsourced services, making them vulnerable to data breaches and compliance violations. According to
